ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotechs Trim Staff

April 23, 2007 | APPEARED IN VOLUME 85, ISSUE 17

Vaccine developer Avant Immunotherapeutics is cutting 30% of its staff and shuttering its St. Louis research facility in an effort to lower costs by 18% in the next two years. All research activities will be moved to the company's Needham, Mass., headquarters, which will house roughly 60 employees once the restructuring is complete in September. Avant will forgo investments in biodefense research and focus on viral and bacterial vaccines. Separately, Genaera is eliminating 30% of its workforce, or 10 employees, as it focuses its research on the development of trodusquemine for obesity and an anti-interleukin-9 antibody for the treatment of asthma.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment